electroCore, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $67.4M
- Price
- $10.52
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.04%
- Volume
- 59.9K
About
electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering, the gammaCore Sapphire, is a portable, rechargeable, and refillable device intended for either regular or intermittent use over many years. Established in 2005, its corporate headquarters are situated in Rockaway, New Jersey.
Quick stats
Shares outstanding8.3M
Computed float4.9M
Float / shares59.1%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001560258
Websitehttps://www.electrocore.com
AI Summary
AI-generated1/26
majorbullishearnings
electroCore Announces Second Quarter 2026 Financial Results
electroCore reported Q2 2026 revenue of $9.5 million, up 28% year-over-year, driven by growth in VA prescription sales and Quell products.
The company raised its full-year 2026 revenue guidance to greater than 30% growth and expects to achieve positive Adjusted EBITDA in the third quarter of 2027.
Adjusted EBITDA net loss improved 26% to $1.8 million, while the GAAP net loss narrowed to $3.1 million from $3.7 million in the prior year.
Red flags
- Cash position decreased to $10.0 million from $11.6 million at year-end 2025